{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:03Z","timestamp":1780605663546,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by abnormal eosinophilia and extravascular eosinophilic granuloma formation. Conventional treatments combining glucocorticoids and immunosuppressants can alleviate the condition in most patients with EGPA. However, the efficacy of blocking tumor necrosis factor (TNF)-\u03b1-mediated inflammatory reactions in managing EGPA remains controversial. Here, we report a case of refractory EGPA that did not respond to glucocorticoid pulse therapy and adequate cyclophosphamide. The disease was ultimately controlled through the coadministration of etanercept.<\/jats:p>","DOI":"10.3389\/fphar.2025.1555377","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:46:06Z","timestamp":1752126366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Coadministration of TNF-\u03b1 blockade as an effective adjunctive strategy in the treatment of ANCA-negative EGPA with refractory peripheral neuropathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Dabin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory churg-strauss-syndrome (css) by tnf-alpha blockade","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jaci.2007.10.028","article-title":"Targeting tnf-alpha: a novel therapeutic approach for asthma","volume":"121","author":"Brightling","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-070912-133235","article-title":"Anti-B cell antibody therapies for inflammatory rheumatic diseases","volume":"65","author":"Faurschou","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1073\/pnas.1015476108","article-title":"Tnf-alpha from inflammatory dendritic cells (dcs) regulates lung Il-17a\/Il-5 levels and neutrophilia Versus eosinophilia during persistent fungal infection","volume":"108","author":"Fei","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13223-022-00653-7","article-title":"Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab","volume":"18","author":"Kai","year":"2022","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e90298","DOI":"10.1371\/journal.pone.0090298","article-title":"Tumour necrosis factor-\u03b1 regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-\u03baB and AP-1","volume":"9","author":"Kankaanranta","year":"2014","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","article-title":"Mepolizumab: first global approval","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/s0140-6736(00)03496-6","article-title":"Effects of an Interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/thx.2007.086314","article-title":"The role of a soluble tnfalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial","volume":"63","author":"Morjaria","year":"2008","journal-title":"Thorax"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1726","DOI":"10.1212\/WNL.0000000000009309","article-title":"Differential clinicopathologic features of egpa-associated neuropathy with and without anca","volume":"94","author":"Nishi","year":"2020","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2015.04.016","article-title":"Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases","volume":"83","author":"Novikov","year":"2016","journal-title":"Jt. Bone Spine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for anca-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab Versus cyclophosphamide for anca-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-Month Follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.rhu.0000120897.08819.ac","article-title":"The use of infliximab in a patient with steroid-dependent Churg-Strauss syndrome","volume":"10","author":"Tiliakos","year":"2004","journal-title":"J. Clin. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1468-1331.2009.02902.x","article-title":"Neurologic complications of churg-strauss Syndrome--a prospective monocentric study","volume":"17","author":"Wolf","year":"2010","journal-title":"Eur. J. Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1555377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:13:38Z","timestamp":1752149618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1555377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":19,"alternative-id":["10.3389\/fphar.2025.1555377"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1555377","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"1555377"}}